Addex Therapeutics Ltd. Quarterly Research And Development Expense in CHF from Q2 2021 to Q2 2023

Taxonomy & unit
ifrs-full: CHF
Summary
Addex Therapeutics Ltd. annual/quarterly Research And Development Expense history and growth rate from Q2 2021 to Q2 2023.
  • Addex Therapeutics Ltd. Research And Development Expense for the quarter ending June 30, 2023 was ₣1.88M, a 67.4% decline year-over-year.
  • Addex Therapeutics Ltd. annual Research And Development Expense for 2023 was ₣6.96M, a 52.5% decline from 2022.
  • Addex Therapeutics Ltd. annual Research And Development Expense for 2022 was ₣14.7M, a 14.2% increase from 2021.
  • Addex Therapeutics Ltd. annual Research And Development Expense for 2021 was ₣12.8M, a 23.8% increase from 2020.
Research And Development Expense, Quarterly (CHF)
Research And Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 1.88M -3.87M -67.4% Apr 1, 2023 Jun 30, 2023 6-K/A 2023-12-21
Q2 2022 5.75M +2.02M +54% Apr 1, 2022 Jun 30, 2022 6-K/A 2023-12-21
Q2 2021 3.73M Apr 1, 2021 Jun 30, 2021 6-K/A 2022-09-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.